This trial will look at the best dose and side effects of SOT102 given alone or with other cancer drugs for people with stomach or pancreatic cancer that has spread and cannot be removed by surgery.
2 Primary · 27 Secondary · Reporting Duration: From the date of the patient's signing the ICF until the end of the trial, assessed up to approximately 4 years
Experimental Treatment
269 Total Participants · 1 Treatment Group
Primary Treatment: SOT102 · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: